Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma

[1]  L. Sequist,et al.  24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[3]  M. Najafi,et al.  Cyclooxygenase‐2 in cancer: A review , 2018, Journal of cellular physiology.

[4]  Lin Lu,et al.  Data mining of the cancer-related lncRNAs GO terms and KEGG pathways by using mRMR method. , 2018, Mathematical biosciences.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  A. Madabhushi,et al.  Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.

[7]  M. Bros,et al.  Interleukin-1 Beta—A Friend or Foe in Malignancies? , 2018, International journal of molecular sciences.

[8]  Sang Kook Lee,et al.  Long noncoding RNAs in cancer cells. , 2018, Cancer letters.

[9]  P. Forde,et al.  Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[10]  Lei Cao,et al.  Network analysis of DEGs and verification experiments reveal the notable roles of PTTG1 and MMP9 in lung cancer , 2017, Oncology letters.

[11]  Hanmei Xu,et al.  Tumor-related interleukins: old validated targets for new anti-cancer drug development , 2017, Molecular Cancer.

[12]  Anisur Rahman,et al.  Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus , 2017, Clinical Reviews in Allergy & Immunology.

[13]  Xiangyin Kong,et al.  The use of Gene Ontology terms and KEGG pathways for analysis and prediction of oncogenes. , 2016, Biochimica et biophysica acta.

[14]  Gwénaël Le Teuff,et al.  Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Hui-Yuen,et al.  Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus , 2016, Lupus.

[16]  David R Jones,et al.  Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ning Wang,et al.  Cancer survival in China, 2003–2005: A population‐based study , 2015, International journal of cancer.

[18]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[19]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[20]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[21]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[22]  N. Naykoo,et al.  Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non small cell lung cancer☆ , 2014, Meta gene.

[23]  Y. Iwakura,et al.  Excess IL-1 Signaling Enhances the Development of Th17 Cells by Downregulating TGF-β–Induced Foxp3 Expression , 2014, The Journal of Immunology.

[24]  Edward S. Kim,et al.  Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy , 2013, Clinical Cancer Research.

[25]  Edward S. Kim,et al.  Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[26]  Shin-ya Ogata,et al.  New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  M. Ladanyi,et al.  KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma , 2013, Modern Pathology.

[28]  Michael Thomas,et al.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Ming You,et al.  MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. , 2012, Carcinogenesis.

[30]  J. Luketich,et al.  Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. , 2011, The Journal of surgical research.

[31]  Garret A. FitzGerald,et al.  Prostaglandins and Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[32]  H. Herfarth,et al.  The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer , 2010, The Journal of experimental medicine.

[33]  E. Giovannucci,et al.  Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer , 2008, Clinical Cancer Research.

[34]  S. Natsugoe,et al.  Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[35]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[36]  David Liu,et al.  DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis , 2007, BMC Bioinformatics.

[37]  C. Dinarello,et al.  The paradox of pro-inflammatory cytokines in cancer , 2006, Cancer and Metastasis Reviews.

[38]  G. Scagliotti,et al.  Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. , 2003, Lung cancer.

[39]  M. Monden,et al.  Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[41]  D. Scollard,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. , 1998, Journal of the National Cancer Institute.

[42]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[43]  R. Newton,et al.  Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity , 1988, The Journal of experimental medicine.

[44]  B. Autran,et al.  rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2. , 1987, Journal of immunology.

[45]  P. Lipsky,et al.  The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. , 1983, Journal of immunology.

[46]  K. Kerr,et al.  PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. , 2018, Cancer treatment reviews.

[47]  G. Schett,et al.  Interleukin-1 function and role in rheumatic disease , 2016, Nature Reviews Rheumatology.

[48]  J. Warrington,et al.  The affymetrix GeneChip platform: an overview. , 2006, Methods in enzymology.